Pathogenesis and medical therapy of primary sclerosing cholangitis. Any news?
| Autor: | van den Arie Berg, Plm Jansen |
|---|---|
| Přispěvatelé: | Other departments |
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Cholagogues and Choleretics medicine.medical_treatment Cholangitis Sclerosing Anti-Inflammatory Agents Inflammation Inflammatory bowel disease Gastroenterology Primary sclerosing cholangitis Primary biliary cirrhosis Cholestasis Fibrosis Bile Ducts Extrahepatic Internal medicine medicine Humans Hepatology business.industry medicine.disease Cytokine Bile Ducts Intrahepatic Rheumatoid arthritis Immunology Cytokines medicine.symptom business Immunosuppressive Agents |
| Zdroj: | European journal of gastroenterology & hepatology, 11(2), 121-124. Lippincott Williams and Wilkins |
| ISSN: | 0954-691X |
| Popis: | Primary sclerosing cholangitis is characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts. Medical therapy has focused on anticholestatic, antiinflammatory and immunosuppressive drugs. Although inflammation, fibrosis and cholestasis may all occur at the same time, inflammation dominates the early phase and fibrosis and cholestasis the later stages. With inflammatory bowel disease and rheumatoid arthritis as stimulants, research on anti-inflammatory drugs is in a very active stage, with an emphasis on cytokines and cytokine antagonists. For patients with primary sclerosing cholestasis to fully benefit from these developments, it is necessary to define the early disease stage that constitutes a potential therapeutic window for these agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|